肺がんバイオマーカーのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Lung Cancer Biomarkers Market Insights, Forecast to 2028

• レポートコード：QY2207E09676 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療機器

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の肺がんバイオマーカーの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に肺がんバイオマーカーの世界市場のxxx％を占める「タンパク質バイオマーカー」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「診断」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の肺がんバイオマーカーの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの肺がんバイオマーカー市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの肺がんバイオマーカー市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 肺がんバイオマーカーのグローバル主要メーカーには、Bio-Rad Laboratories、Roche Diagnostics、Qiagen、Illumina、GE Healthcare、Agilent Technologies、Biomerieux SA、Merck、Abbott Laboratories、Becton, Dickinson and Company、Danaher Corporation、Myriad Genetics、Sysmex Corporation、Hologicなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 肺がんバイオマーカー市場は、種類と用途によって区分されます。世界の肺がんバイオマーカー市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 タンパク質バイオマーカー、遺伝子バイオマーカー 【用途別セグメント】 診断、研究、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 肺がんバイオマーカー製品概要 - 種類別市場（タンパク質バイオマーカー、遺伝子バイオマーカー） - 用途別市場（診断、研究、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の肺がんバイオマーカー販売量予測2017-2028 - 世界の肺がんバイオマーカー売上予測2017-2028 - 肺がんバイオマーカーの地域別販売量 - 肺がんバイオマーカーの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別肺がんバイオマーカー販売量 - 主要メーカー別肺がんバイオマーカー売上 - 主要メーカー別肺がんバイオマーカー価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（タンパク質バイオマーカー、遺伝子バイオマーカー） - 肺がんバイオマーカーの種類別販売量 - 肺がんバイオマーカーの種類別売上 - 肺がんバイオマーカーの種類別価格 ・用途別市場規模（診断、研究、その他） - 肺がんバイオマーカーの用途別販売量 - 肺がんバイオマーカーの用途別売上 - 肺がんバイオマーカーの用途別価格 ・北米市場 - 北米の肺がんバイオマーカー市場規模（種類別、用途別） - 主要国別の肺がんバイオマーカー市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの肺がんバイオマーカー市場規模（種類別、用途別） - 主要国別の肺がんバイオマーカー市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の肺がんバイオマーカー市場規模（種類別、用途別） - 主要国別の肺がんバイオマーカー市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の肺がんバイオマーカー市場規模（種類別、用途別） - 主要国別の肺がんバイオマーカー市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの肺がんバイオマーカー市場規模（種類別、用途別） - 主要国別の肺がんバイオマーカー市場規模（トルコ、サウジアラビア） ・企業情報 Bio-Rad Laboratories、Roche Diagnostics、Qiagen、Illumina、GE Healthcare、Agilent Technologies、Biomerieux SA、Merck、Abbott Laboratories、Becton, Dickinson and Company、Danaher Corporation、Myriad Genetics、Sysmex Corporation、Hologic ・産業チェーン及び販売チャネル分析 - 肺がんバイオマーカーの産業チェーン分析 - 肺がんバイオマーカーの原材料 - 肺がんバイオマーカーの生産プロセス - 肺がんバイオマーカーの販売及びマーケティング - 肺がんバイオマーカーの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 肺がんバイオマーカーの産業動向 - 肺がんバイオマーカーのマーケットドライバー - 肺がんバイオマーカーの課題 - 肺がんバイオマーカーの阻害要因 ・主な調査結果

Market Analysis and Insights: Global Lung Cancer Biomarkers Market
Due to the COVID-19 pandemic, the global Lung Cancer Biomarkers market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Protein Biomarker accounting for % of the Lung Cancer Biomarkers global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Diagnostics segment is altered to an % CAGR throughout this forecast period.
China Lung Cancer Biomarkers market size is valued at US$ million in 2021, while the US and Europe Lung Cancer Biomarkers are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Lung Cancer Biomarkers landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Lung Cancer Biomarkers include Bio-Rad Laboratories, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Agilent Technologies, Biomerieux SA, Merck and Abbott Laboratories, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Lung Cancer Biomarkers Scope and Segment
Lung Cancer Biomarkers market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Lung Cancer Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Protein Biomarker
Genetic Biomarker
Segment by Application
Diagnostics
Research
Others
By Company
Bio-Rad Laboratories
Roche Diagnostics
Qiagen
Illumina
GE Healthcare
Agilent Technologies
Biomerieux SA
Merck
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation
Myriad Genetics
Sysmex Corporation
Hologic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Lung Cancer Biomarkers Product Introduction
1.2 Market by Type
1.2.1 Global Lung Cancer Biomarkers Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Protein Biomarker
1.2.3 Genetic Biomarker
1.3 Market by Application
1.3.1 Global Lung Cancer Biomarkers Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Diagnostics
1.3.3 Research
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Lung Cancer Biomarkers Sales Estimates and Forecasts 2017-2028
2.2 Global Lung Cancer Biomarkers Revenue Estimates and Forecasts 2017-2028
2.3 Global Lung Cancer Biomarkers Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Lung Cancer Biomarkers Sales by Region
2.4.1 Global Lung Cancer Biomarkers Sales by Region (2017-2022)
2.4.2 Global Sales Lung Cancer Biomarkers by Region (2023-2028)
2.5 Global Lung Cancer Biomarkers Revenue by Region
2.5.1 Global Lung Cancer Biomarkers Revenue by Region (2017-2022)
2.5.2 Global Lung Cancer Biomarkers Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Lung Cancer Biomarkers Sales by Manufacturers
3.1.1 Global Top Lung Cancer Biomarkers Manufacturers by Sales (2017-2022)
3.1.2 Global Lung Cancer Biomarkers Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Lung Cancer Biomarkers in 2021
3.2 Global Lung Cancer Biomarkers Revenue by Manufacturers
3.2.1 Global Lung Cancer Biomarkers Revenue by Manufacturers (2017-2022)
3.2.2 Global Lung Cancer Biomarkers Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Lung Cancer Biomarkers Revenue in 2021
3.3 Global Lung Cancer Biomarkers Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Lung Cancer Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Lung Cancer Biomarkers Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Lung Cancer Biomarkers Sales by Type
4.1.1 Global Lung Cancer Biomarkers Historical Sales by Type (2017-2022)
4.1.2 Global Lung Cancer Biomarkers Forecasted Sales by Type (2023-2028)
4.1.3 Global Lung Cancer Biomarkers Sales Market Share by Type (2017-2028)
4.2 Global Lung Cancer Biomarkers Revenue by Type
4.2.1 Global Lung Cancer Biomarkers Historical Revenue by Type (2017-2022)
4.2.2 Global Lung Cancer Biomarkers Forecasted Revenue by Type (2023-2028)
4.2.3 Global Lung Cancer Biomarkers Revenue Market Share by Type (2017-2028)
4.3 Global Lung Cancer Biomarkers Price by Type
4.3.1 Global Lung Cancer Biomarkers Price by Type (2017-2022)
4.3.2 Global Lung Cancer Biomarkers Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Lung Cancer Biomarkers Sales by Application
5.1.1 Global Lung Cancer Biomarkers Historical Sales by Application (2017-2022)
5.1.2 Global Lung Cancer Biomarkers Forecasted Sales by Application (2023-2028)
5.1.3 Global Lung Cancer Biomarkers Sales Market Share by Application (2017-2028)
5.2 Global Lung Cancer Biomarkers Revenue by Application
5.2.1 Global Lung Cancer Biomarkers Historical Revenue by Application (2017-2022)
5.2.2 Global Lung Cancer Biomarkers Forecasted Revenue by Application (2023-2028)
5.2.3 Global Lung Cancer Biomarkers Revenue Market Share by Application (2017-2028)
5.3 Global Lung Cancer Biomarkers Price by Application
5.3.1 Global Lung Cancer Biomarkers Price by Application (2017-2022)
5.3.2 Global Lung Cancer Biomarkers Price Forecast by Application (2023-2028)
6 North America
6.1 North America Lung Cancer Biomarkers Market Size by Type
6.1.1 North America Lung Cancer Biomarkers Sales by Type (2017-2028)
6.1.2 North America Lung Cancer Biomarkers Revenue by Type (2017-2028)
6.2 North America Lung Cancer Biomarkers Market Size by Application
6.2.1 North America Lung Cancer Biomarkers Sales by Application (2017-2028)
6.2.2 North America Lung Cancer Biomarkers Revenue by Application (2017-2028)
6.3 North America Lung Cancer Biomarkers Market Size by Country
6.3.1 North America Lung Cancer Biomarkers Sales by Country (2017-2028)
6.3.2 North America Lung Cancer Biomarkers Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Lung Cancer Biomarkers Market Size by Type
7.1.1 Europe Lung Cancer Biomarkers Sales by Type (2017-2028)
7.1.2 Europe Lung Cancer Biomarkers Revenue by Type (2017-2028)
7.2 Europe Lung Cancer Biomarkers Market Size by Application
7.2.1 Europe Lung Cancer Biomarkers Sales by Application (2017-2028)
7.2.2 Europe Lung Cancer Biomarkers Revenue by Application (2017-2028)
7.3 Europe Lung Cancer Biomarkers Market Size by Country
7.3.1 Europe Lung Cancer Biomarkers Sales by Country (2017-2028)
7.3.2 Europe Lung Cancer Biomarkers Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Lung Cancer Biomarkers Market Size by Type
8.1.1 Asia Pacific Lung Cancer Biomarkers Sales by Type (2017-2028)
8.1.2 Asia Pacific Lung Cancer Biomarkers Revenue by Type (2017-2028)
8.2 Asia Pacific Lung Cancer Biomarkers Market Size by Application
8.2.1 Asia Pacific Lung Cancer Biomarkers Sales by Application (2017-2028)
8.2.2 Asia Pacific Lung Cancer Biomarkers Revenue by Application (2017-2028)
8.3 Asia Pacific Lung Cancer Biomarkers Market Size by Region
8.3.1 Asia Pacific Lung Cancer Biomarkers Sales by Region (2017-2028)
8.3.2 Asia Pacific Lung Cancer Biomarkers Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Lung Cancer Biomarkers Market Size by Type
9.1.1 Latin America Lung Cancer Biomarkers Sales by Type (2017-2028)
9.1.2 Latin America Lung Cancer Biomarkers Revenue by Type (2017-2028)
9.2 Latin America Lung Cancer Biomarkers Market Size by Application
9.2.1 Latin America Lung Cancer Biomarkers Sales by Application (2017-2028)
9.2.2 Latin America Lung Cancer Biomarkers Revenue by Application (2017-2028)
9.3 Latin America Lung Cancer Biomarkers Market Size by Country
9.3.1 Latin America Lung Cancer Biomarkers Sales by Country (2017-2028)
9.3.2 Latin America Lung Cancer Biomarkers Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Lung Cancer Biomarkers Market Size by Type
10.1.1 Middle East and Africa Lung Cancer Biomarkers Sales by Type (2017-2028)
10.1.2 Middle East and Africa Lung Cancer Biomarkers Revenue by Type (2017-2028)
10.2 Middle East and Africa Lung Cancer Biomarkers Market Size by Application
10.2.1 Middle East and Africa Lung Cancer Biomarkers Sales by Application (2017-2028)
10.2.2 Middle East and Africa Lung Cancer Biomarkers Revenue by Application (2017-2028)
10.3 Middle East and Africa Lung Cancer Biomarkers Market Size by Country
10.3.1 Middle East and Africa Lung Cancer Biomarkers Sales by Country (2017-2028)
10.3.2 Middle East and Africa Lung Cancer Biomarkers Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Bio-Rad Laboratories
11.1.1 Bio-Rad Laboratories Corporation Information
11.1.2 Bio-Rad Laboratories Overview
11.1.3 Bio-Rad Laboratories Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Bio-Rad Laboratories Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bio-Rad Laboratories Recent Developments
11.2 Roche Diagnostics
11.2.1 Roche Diagnostics Corporation Information
11.2.2 Roche Diagnostics Overview
11.2.3 Roche Diagnostics Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Roche Diagnostics Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Roche Diagnostics Recent Developments
11.3 Qiagen
11.3.1 Qiagen Corporation Information
11.3.2 Qiagen Overview
11.3.3 Qiagen Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Qiagen Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Qiagen Recent Developments
11.4 Illumina
11.4.1 Illumina Corporation Information
11.4.2 Illumina Overview
11.4.3 Illumina Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Illumina Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Illumina Recent Developments
11.5 GE Healthcare
11.5.1 GE Healthcare Corporation Information
11.5.2 GE Healthcare Overview
11.5.3 GE Healthcare Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 GE Healthcare Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 GE Healthcare Recent Developments
11.6 Agilent Technologies
11.6.1 Agilent Technologies Corporation Information
11.6.2 Agilent Technologies Overview
11.6.3 Agilent Technologies Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Agilent Technologies Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Agilent Technologies Recent Developments
11.7 Biomerieux SA
11.7.1 Biomerieux SA Corporation Information
11.7.2 Biomerieux SA Overview
11.7.3 Biomerieux SA Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Biomerieux SA Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Biomerieux SA Recent Developments
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Overview
11.8.3 Merck Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Merck Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Merck Recent Developments
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Corporation Information
11.9.2 Abbott Laboratories Overview
11.9.3 Abbott Laboratories Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Abbott Laboratories Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Abbott Laboratories Recent Developments
11.10 Becton, Dickinson and Company
11.10.1 Becton, Dickinson and Company Corporation Information
11.10.2 Becton, Dickinson and Company Overview
11.10.3 Becton, Dickinson and Company Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Becton, Dickinson and Company Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Becton, Dickinson and Company Recent Developments
11.11 Danaher Corporation
11.11.1 Danaher Corporation Corporation Information
11.11.2 Danaher Corporation Overview
11.11.3 Danaher Corporation Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Danaher Corporation Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Danaher Corporation Recent Developments
11.12 Myriad Genetics
11.12.1 Myriad Genetics Corporation Information
11.12.2 Myriad Genetics Overview
11.12.3 Myriad Genetics Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Myriad Genetics Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Myriad Genetics Recent Developments
11.13 Sysmex Corporation
11.13.1 Sysmex Corporation Corporation Information
11.13.2 Sysmex Corporation Overview
11.13.3 Sysmex Corporation Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Sysmex Corporation Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Sysmex Corporation Recent Developments
11.14 Hologic
11.14.1 Hologic Corporation Information
11.14.2 Hologic Overview
11.14.3 Hologic Lung Cancer Biomarkers Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Hologic Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Hologic Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Lung Cancer Biomarkers Industry Chain Analysis
12.2 Lung Cancer Biomarkers Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Lung Cancer Biomarkers Production Mode & Process
12.4 Lung Cancer Biomarkers Sales and Marketing
12.4.1 Lung Cancer Biomarkers Sales Channels
12.4.2 Lung Cancer Biomarkers Distributors
12.5 Lung Cancer Biomarkers Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Lung Cancer Biomarkers Industry Trends
13.2 Lung Cancer Biomarkers Market Drivers
13.3 Lung Cancer Biomarkers Market Challenges
13.4 Lung Cancer Biomarkers Market Restraints
14 Key Findings in The Global Lung Cancer Biomarkers Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Lung Cancer Biomarkers Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Protein Biomarker
Table 3. Major Manufacturers of Genetic Biomarker
Table 4. Global Lung Cancer Biomarkers Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Lung Cancer Biomarkers Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Lung Cancer Biomarkers Sales by Region (2017-2022) & (Units)
Table 7. Global Lung Cancer Biomarkers Sales Market Share by Region (2017-2022)
Table 8. Global Lung Cancer Biomarkers Sales by Region (2023-2028) & (Units)
Table 9. Global Lung Cancer Biomarkers Sales Market Share by Region (2023-2028)
Table 10. Global Lung Cancer Biomarkers Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Lung Cancer Biomarkers Revenue Market Share by Region (2017-2022)
Table 12. Global Lung Cancer Biomarkers Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Lung Cancer Biomarkers Revenue Market Share by Region (2023-2028)
Table 14. Global Lung Cancer Biomarkers Sales by Manufacturers (2017-2022) & (Units)
Table 15. Global Lung Cancer Biomarkers Sales Share by Manufacturers (2017-2022)
Table 16. Global Lung Cancer Biomarkers Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Lung Cancer Biomarkers Revenue Share by Manufacturers (2017-2022)
Table 18. Lung Cancer Biomarkers Price by Manufacturers (2017-2022) &(US$/Unit)
Table 19. Global Lung Cancer Biomarkers Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Lung Cancer Biomarkers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Biomarkers as of 2021)
Table 21. Lung Cancer Biomarkers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Lung Cancer Biomarkers Product Offered
Table 23. Date of Manufacturers Enter into Lung Cancer Biomarkers Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Lung Cancer Biomarkers Sales by Type (2017-2022) & (Units)
Table 26. Global Lung Cancer Biomarkers Sales by Type (2023-2028) & (Units)
Table 27. Global Lung Cancer Biomarkers Sales Share by Type (2017-2022)
Table 28. Global Lung Cancer Biomarkers Sales Share by Type (2023-2028)
Table 29. Global Lung Cancer Biomarkers Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Lung Cancer Biomarkers Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Lung Cancer Biomarkers Revenue Share by Type (2017-2022)
Table 32. Global Lung Cancer Biomarkers Revenue Share by Type (2023-2028)
Table 33. Lung Cancer Biomarkers Price by Type (2017-2022) & (US$/Unit)
Table 34. Global Lung Cancer Biomarkers Price Forecast by Type (2023-2028) & (US$/Unit)
Table 35. Global Lung Cancer Biomarkers Sales by Application (2017-2022) & (Units)
Table 36. Global Lung Cancer Biomarkers Sales by Application (2023-2028) & (Units)
Table 37. Global Lung Cancer Biomarkers Sales Share by Application (2017-2022)
Table 38. Global Lung Cancer Biomarkers Sales Share by Application (2023-2028)
Table 39. Global Lung Cancer Biomarkers Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Lung Cancer Biomarkers Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Lung Cancer Biomarkers Revenue Share by Application (2017-2022)
Table 42. Global Lung Cancer Biomarkers Revenue Share by Application (2023-2028)
Table 43. Lung Cancer Biomarkers Price by Application (2017-2022) & (US$/Unit)
Table 44. Global Lung Cancer Biomarkers Price Forecast by Application (2023-2028) & (US$/Unit)
Table 45. North America Lung Cancer Biomarkers Sales by Type (2017-2022) & (Units)
Table 46. North America Lung Cancer Biomarkers Sales by Type (2023-2028) & (Units)
Table 47. North America Lung Cancer Biomarkers Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Lung Cancer Biomarkers Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Lung Cancer Biomarkers Sales by Application (2017-2022) & (Units)
Table 50. North America Lung Cancer Biomarkers Sales by Application (2023-2028) & (Units)
Table 51. North America Lung Cancer Biomarkers Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Lung Cancer Biomarkers Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Lung Cancer Biomarkers Sales by Country (2017-2022) & (Units)
Table 54. North America Lung Cancer Biomarkers Sales by Country (2023-2028) & (Units)
Table 55. North America Lung Cancer Biomarkers Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Lung Cancer Biomarkers Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Lung Cancer Biomarkers Sales by Type (2017-2022) & (Units)
Table 58. Europe Lung Cancer Biomarkers Sales by Type (2023-2028) & (Units)
Table 59. Europe Lung Cancer Biomarkers Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Lung Cancer Biomarkers Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Lung Cancer Biomarkers Sales by Application (2017-2022) & (Units)
Table 62. Europe Lung Cancer Biomarkers Sales by Application (2023-2028) & (Units)
Table 63. Europe Lung Cancer Biomarkers Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Lung Cancer Biomarkers Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Lung Cancer Biomarkers Sales by Country (2017-2022) & (Units)
Table 66. Europe Lung Cancer Biomarkers Sales by Country (2023-2028) & (Units)
Table 67. Europe Lung Cancer Biomarkers Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Lung Cancer Biomarkers Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Lung Cancer Biomarkers Sales by Type (2017-2022) & (Units)
Table 70. Asia Pacific Lung Cancer Biomarkers Sales by Type (2023-2028) & (Units)
Table 71. Asia Pacific Lung Cancer Biomarkers Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Lung Cancer Biomarkers Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Lung Cancer Biomarkers Sales by Application (2017-2022) & (Units)
Table 74. Asia Pacific Lung Cancer Biomarkers Sales by Application (2023-2028) & (Units)
Table 75. Asia Pacific Lung Cancer Biomarkers Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Lung Cancer Biomarkers Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Lung Cancer Biomarkers Sales by Region (2017-2022) & (Units)
Table 78. Asia Pacific Lung Cancer Biomarkers Sales by Region (2023-2028) & (Units)
Table 79. Asia Pacific Lung Cancer Biomarkers Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Lung Cancer Biomarkers Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Lung Cancer Biomarkers Sales by Type (2017-2022) & (Units)
Table 82. Latin America Lung Cancer Biomarkers Sales by Type (2023-2028) & (Units)
Table 83. Latin America Lung Cancer Biomarkers Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Lung Cancer Biomarkers Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Lung Cancer Biomarkers Sales by Application (2017-2022) & (Units)
Table 86. Latin America Lung Cancer Biomarkers Sales by Application (2023-2028) & (Units)
Table 87. Latin America Lung Cancer Biomarkers Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Lung Cancer Biomarkers Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Lung Cancer Biomarkers Sales by Country (2017-2022) & (Units)
Table 90. Latin America Lung Cancer Biomarkers Sales by Country (2023-2028) & (Units)
Table 91. Latin America Lung Cancer Biomarkers Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Lung Cancer Biomarkers Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Lung Cancer Biomarkers Sales by Type (2017-2022) & (Units)
Table 94. Middle East and Africa Lung Cancer Biomarkers Sales by Type (2023-2028) & (Units)
Table 95. Middle East and Africa Lung Cancer Biomarkers Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Lung Cancer Biomarkers Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Lung Cancer Biomarkers Sales by Application (2017-2022) & (Units)
Table 98. Middle East and Africa Lung Cancer Biomarkers Sales by Application (2023-2028) & (Units)
Table 99. Middle East and Africa Lung Cancer Biomarkers Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Lung Cancer Biomarkers Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Lung Cancer Biomarkers Sales by Country (2017-2022) & (Units)
Table 102. Middle East and Africa Lung Cancer Biomarkers Sales by Country (2023-2028) & (Units)
Table 103. Middle East and Africa Lung Cancer Biomarkers Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Lung Cancer Biomarkers Revenue by Country (2023-2028) & (US$ Million)
Table 105. Bio-Rad Laboratories Corporation Information
Table 106. Bio-Rad Laboratories Description and Major Businesses
Table 107. Bio-Rad Laboratories Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 108. Bio-Rad Laboratories Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Bio-Rad Laboratories Recent Developments
Table 110. Roche Diagnostics Corporation Information
Table 111. Roche Diagnostics Description and Major Businesses
Table 112. Roche Diagnostics Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 113. Roche Diagnostics Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Roche Diagnostics Recent Developments
Table 115. Qiagen Corporation Information
Table 116. Qiagen Description and Major Businesses
Table 117. Qiagen Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 118. Qiagen Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Qiagen Recent Developments
Table 120. Illumina Corporation Information
Table 121. Illumina Description and Major Businesses
Table 122. Illumina Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 123. Illumina Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Illumina Recent Developments
Table 125. GE Healthcare Corporation Information
Table 126. GE Healthcare Description and Major Businesses
Table 127. GE Healthcare Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 128. GE Healthcare Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. GE Healthcare Recent Developments
Table 130. Agilent Technologies Corporation Information
Table 131. Agilent Technologies Description and Major Businesses
Table 132. Agilent Technologies Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 133. Agilent Technologies Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Agilent Technologies Recent Developments
Table 135. Biomerieux SA Corporation Information
Table 136. Biomerieux SA Description and Major Businesses
Table 137. Biomerieux SA Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 138. Biomerieux SA Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Biomerieux SA Recent Developments
Table 140. Merck Corporation Information
Table 141. Merck Description and Major Businesses
Table 142. Merck Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 143. Merck Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Merck Recent Developments
Table 145. Abbott Laboratories Corporation Information
Table 146. Abbott Laboratories Description and Major Businesses
Table 147. Abbott Laboratories Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 148. Abbott Laboratories Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Abbott Laboratories Recent Developments
Table 150. Becton, Dickinson and Company Corporation Information
Table 151. Becton, Dickinson and Company Description and Major Businesses
Table 152. Becton, Dickinson and Company Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 153. Becton, Dickinson and Company Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Becton, Dickinson and Company Recent Developments
Table 155. Danaher Corporation Corporation Information
Table 156. Danaher Corporation Description and Major Businesses
Table 157. Danaher Corporation Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 158. Danaher Corporation Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. Danaher Corporation Recent Developments
Table 160. Myriad Genetics Corporation Information
Table 161. Myriad Genetics Description and Major Businesses
Table 162. Myriad Genetics Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 163. Myriad Genetics Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. Myriad Genetics Recent Developments
Table 165. Sysmex Corporation Corporation Information
Table 166. Sysmex Corporation Description and Major Businesses
Table 167. Sysmex Corporation Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 168. Sysmex Corporation Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 169. Sysmex Corporation Recent Developments
Table 170. Hologic Corporation Information
Table 171. Hologic Description and Major Businesses
Table 172. Hologic Lung Cancer Biomarkers Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 173. Hologic Lung Cancer Biomarkers Product Model Numbers, Pictures, Descriptions and Specifications
Table 174. Hologic Recent Developments
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Lung Cancer Biomarkers Distributors List
Table 178. Lung Cancer Biomarkers Customers List
Table 179. Lung Cancer Biomarkers Market Trends
Table 180. Lung Cancer Biomarkers Market Drivers
Table 181. Lung Cancer Biomarkers Market Challenges
Table 182. Lung Cancer Biomarkers Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Lung Cancer Biomarkers Product Picture
Figure 3. Global Lung Cancer Biomarkers Market Share by Type in 2021 & 2028
Figure 3. Protein Biomarker Product Picture
Figure 4. Genetic Biomarker Product Picture
Figure 5. Global Lung Cancer Biomarkers Market Share by Application in 2021 & 2028
Figure 6. Diagnostics
Figure 7. Research
Figure 8. Others
Figure 9. Lung Cancer Biomarkers Report Years Considered
Figure 10. Global Lung Cancer Biomarkers Sales 2017-2028 (Units)
Figure 11. Global Lung Cancer Biomarkers Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Lung Cancer Biomarkers Revenue 2017-2028 (US$ Million)
Figure 13. Global Lung Cancer Biomarkers Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 14. Global Lung Cancer Biomarkers Sales Market Share by Region (2017-2022)
Figure 15. Global Lung Cancer Biomarkers Sales Market Share by Region (2023-2028)
Figure 16. North America Lung Cancer Biomarkers Sales YoY (2017-2028) & (Units)
Figure 17. North America Lung Cancer Biomarkers Revenue YoY (2017-2028) & (US$ Million)
Figure 18. Europe Lung Cancer Biomarkers Sales YoY (2017-2028) & (Units)
Figure 19. Europe Lung Cancer Biomarkers Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Asia-Pacific Lung Cancer Biomarkers Sales YoY (2017-2028) & (Units)
Figure 21. Asia-Pacific Lung Cancer Biomarkers Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Latin America Lung Cancer Biomarkers Sales YoY (2017-2028) & (Units)
Figure 23. Latin America Lung Cancer Biomarkers Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Middle East & Africa Lung Cancer Biomarkers Sales YoY (2017-2028) & (Units)
Figure 25. Middle East & Africa Lung Cancer Biomarkers Revenue YoY (2017-2028) & (US$ Million)
Figure 26. The Lung Cancer Biomarkers Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 27. The Top 5 and 10 Largest Manufacturers of Lung Cancer Biomarkers in the World: Market Share by Lung Cancer Biomarkers Revenue in 2021
Figure 28. Global Lung Cancer Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 29. Global Lung Cancer Biomarkers Sales Market Share by Type (2017-2028)
Figure 30. Global Lung Cancer Biomarkers Revenue Market Share by Type (2017-2028)
Figure 31. Global Lung Cancer Biomarkers Sales Market Share by Application (2017-2028)
Figure 32. Global Lung Cancer Biomarkers Revenue Market Share by Application (2017-2028)
Figure 33. North America Lung Cancer Biomarkers Sales Market Share by Type (2017-2028)
Figure 34. North America Lung Cancer Biomarkers Revenue Market Share by Type (2017-2028)
Figure 35. North America Lung Cancer Biomarkers Sales Market Share by Application (2017-2028)
Figure 36. North America Lung Cancer Biomarkers Revenue Market Share by Application (2017-2028)
Figure 37. North America Lung Cancer Biomarkers Sales Share by Country (2017-2028)
Figure 38. North America Lung Cancer Biomarkers Revenue Share by Country (2017-2028)
Figure 39. United States Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 40. Canada Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 41. Europe Lung Cancer Biomarkers Sales Market Share by Type (2017-2028)
Figure 42. Europe Lung Cancer Biomarkers Revenue Market Share by Type (2017-2028)
Figure 43. Europe Lung Cancer Biomarkers Sales Market Share by Application (2017-2028)
Figure 44. Europe Lung Cancer Biomarkers Revenue Market Share by Application (2017-2028)
Figure 45. Europe Lung Cancer Biomarkers Sales Share by Country (2017-2028)
Figure 46. Europe Lung Cancer Biomarkers Revenue Share by Country (2017-2028)
Figure 47. Germany Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 48. France Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 49. U.K. Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 50. Italy Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 51. Russia Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 52. Asia Pacific Lung Cancer Biomarkers Sales Market Share by Type (2017-2028)
Figure 53. Asia Pacific Lung Cancer Biomarkers Revenue Market Share by Type (2017-2028)
Figure 54. Asia Pacific Lung Cancer Biomarkers Sales Market Share by Application (2017-2028)
Figure 55. Asia Pacific Lung Cancer Biomarkers Revenue Market Share by Application (2017-2028)
Figure 56. Asia Pacific Lung Cancer Biomarkers Sales Share by Region (2017-2028)
Figure 57. Asia Pacific Lung Cancer Biomarkers Revenue Share by Region (2017-2028)
Figure 58. China Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 59. Japan Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 60. South Korea Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 61. India Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 62. Australia Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 63. China Taiwan Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 64. Indonesia Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 65. Thailand Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 66. Malaysia Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 67. Latin America Lung Cancer Biomarkers Sales Market Share by Type (2017-2028)
Figure 68. Latin America Lung Cancer Biomarkers Revenue Market Share by Type (2017-2028)
Figure 69. Latin America Lung Cancer Biomarkers Sales Market Share by Application (2017-2028)
Figure 70. Latin America Lung Cancer Biomarkers Revenue Market Share by Application (2017-2028)
Figure 71. Latin America Lung Cancer Biomarkers Sales Share by Country (2017-2028)
Figure 72. Latin America Lung Cancer Biomarkers Revenue Share by Country (2017-2028)
Figure 73. Mexico Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 74. Brazil Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 75. Argentina Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 76. Middle East and Africa Lung Cancer Biomarkers Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Lung Cancer Biomarkers Revenue Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Lung Cancer Biomarkers Sales Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Lung Cancer Biomarkers Revenue Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Lung Cancer Biomarkers Sales Share by Country (2017-2028)
Figure 81. Middle East and Africa Lung Cancer Biomarkers Revenue Share by Country (2017-2028)
Figure 82. Turkey Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 83. Saudi Arabia Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 84. UAE Lung Cancer Biomarkers Revenue (2017-2028) & (US$ Million)
Figure 85. Lung Cancer Biomarkers Value Chain
Figure 86. Lung Cancer Biomarkers Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

---